Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
University of Cincinnati, Division of Internal Medicine
735
mi
from 02139
Cincinnati, OH
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
University of Cincinnati, Division of Internal Medicine
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Optimed Research, LTD
639
mi
from 02139
Columbus, OH
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Optimed Research, LTD
639
mi
from 02139
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Penn State Milton S. Hershey Medical Center
321
mi
from 02139
Hershey, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Penn State Milton S. Hershey Medical Center
321
mi
from 02139
Hershey, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Asthma Allergy & Pulmonary Associates
268
mi
from 02139
Philadelphia, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Asthma Allergy & Pulmonary Associates
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Children's Hospital of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Children's Hospital of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Highlands Allergy and Asthma Center, PC
712
mi
from 02139
Bristol, TN
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Highlands Allergy and Asthma Center, PC
712
mi
from 02139
Bristol, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
The Paull Allergy and Asthma Clinic, P.A.
1565
mi
from 02139
Bryan, TX
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
The Paull Allergy and Asthma Clinic, P.A.
1565
mi
from 02139
Bryan, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
AARA Research Center
1540
mi
from 02139
Dallas, TX
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
AARA Research Center
1540
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
University of Utah Health Sciences Center
2088
mi
from 02139
Salt Lake City, UT
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
University of Utah Health Sciences Center
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Clinical Research Associates of Tidewater
470
mi
from 02139
Norfolk, VA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Clinical Research Associates of Tidewater
470
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Puget Sound Allergy, Asthma & Immunology
2494
mi
from 02139
Tacoma, WA
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Puget Sound Allergy, Asthma & Immunology
2494
mi
from 02139
Tacoma, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated:  1/22/2018
Allergy and Asthma Research Centre
310
mi
from 02139
Ottawa,
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks
Status: Enrolling
Updated: 1/22/2018
Allergy and Asthma Research Centre
310
mi
from 02139
Ottawa,
Click here to add this to my saved trials
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated:  2/12/2018
UCIMC
2578
mi
from 02139
Orange, CA
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated: 2/12/2018
UCIMC
2578
mi
from 02139
Orange, CA
Click here to add this to my saved trials
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Status: Enrolling
Updated:  2/15/2018
Pavilion Dermatology Suite K
1253
mi
from 02139
Jackson, MS
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Status: Enrolling
Updated: 2/15/2018
Pavilion Dermatology Suite K
1253
mi
from 02139
Jackson, MS
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative site
2599
mi
from 02139
Los Angeles, CA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative site
2599
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
929
mi
from 02139
Atlanta, GA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
929
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
643
mi
from 02139
Ann Arbor, MI
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
643
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
393
mi
from 02139
Buffalo, NY
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
393
mi
from 02139
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
607
mi
from 02139
Durham, NC
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
607
mi
from 02139
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis
476
mi
from 02139
Pittsburgh, PA
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis
476
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
2091
mi
from 02139
Salt Lake City, UT
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
2091
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated:  3/6/2018
Novartis Investigative Site
10095
mi
from 02139
Kogarah,
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Status: Enrolling
Updated: 3/6/2018
Novartis Investigative Site
10095
mi
from 02139
Kogarah,
Click here to add this to my saved trials
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated:  3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
357
mi
from 02139
Baltimore, MD
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Status: Enrolling
Updated: 3/14/2018
R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center
357
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Emory University
934
mi
from 02139
Atlanta, GA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Emory University
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
David Fivenson, M.D. Dermatology, PLLC
647
mi
from 02139
Ann Arbor, MI
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
David Fivenson, M.D. Dermatology, PLLC
647
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Wake Forest University School of Medicine
652
mi
from 02139
Winston-Salem, NC
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Wake Forest University School of Medicine
652
mi
from 02139
Winston-Salem, NC
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Wright State University School of Medicine
708
mi
from 02139
Dayton, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Wright State University School of Medicine
708
mi
from 02139
Dayton, OH
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Stanford Univ Med Ctr
2687
mi
from 02139
Stanford, CA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Stanford Univ Med Ctr
2687
mi
from 02139
Stanford, CA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University of Louisville
821
mi
from 02139
Louisville, KY
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University of Louisville
821
mi
from 02139
Louisville, KY
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Tufts - New England Medical Center
2
mi
from 02139
Boston, MA
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Tufts - New England Medical Center
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University of Michigan
643
mi
from 02139
Ann Arbor, MI
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University of Michigan
643
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Mount Sinai School of Medicine
182
mi
from 02139
New York, NY
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Mount Sinai School of Medicine
182
mi
from 02139
New York, NY
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
University Hospitals of Cleveland
542
mi
from 02139
Cleveland, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
University Hospitals of Cleveland
542
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Foundation
544
mi
from 02139
Cleveland, OH
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Foundation
544
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Providence VA Medical Center, Providence, RI
40
mi
from 02139
Providence, RI
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Providence VA Medical Center, Providence, RI
40
mi
from 02139
Providence, RI
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
2688
mi
from 02139
Palo Alto, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
2688
mi
from 02139
Palo Alto, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA San Diego Healthcare System, San Diego, CA
2576
mi
from 02139
San Diego, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA San Diego Healthcare System, San Diego, CA
2576
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
1763
mi
from 02139
Denver, CO
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
1763
mi
from 02139
Denver, CO
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
1200
mi
from 02139
Bay Pines, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
1200
mi
from 02139
Bay Pines, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Miami VA Healthcare System, Miami, FL
1257
mi
from 02139
Miami, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Miami VA Healthcare System, Miami, FL
1257
mi
from 02139
Miami, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
929
mi
from 02139
Decatur, GA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
929
mi
from 02139
Decatur, GA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
857
mi
from 02139
Hines, IL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
857
mi
from 02139
Hines, IL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2
mi
from 02139
Boston, MA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
1117
mi
from 02139
Minneapolis, MN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
1117
mi
from 02139
Minneapolis, MN
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Durham VA Medical Center, Durham, NC
607
mi
from 02139
Durham, NC
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Durham VA Medical Center, Durham, NC
607
mi
from 02139
Durham, NC
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
270
mi
from 02139
Philadelphia, PA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
270
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
939
mi
from 02139
Nashville, TN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
939
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy and Asthma Relief Experts
2596
mi
from 02139
Granada Hills, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy and Asthma Relief Experts
2596
mi
from 02139
Granada Hills, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy & Asthma Care Center of Southern California
2589
mi
from 02139
Long Beach, CA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy & Asthma Care Center of Southern California
2589
mi
from 02139
Long Beach, CA
Click here to add this to my saved trials